« Back
Home /
vandetanib-hydrochloride

vandetanib-hydrochloride

Manufacturer	InvivoChem LLC
Category	Reagents & Chemicals Molecules
Type	Biochemicals
Specific against	other
Amount	100mg
Item no.	V30291-100mg
CASRN	524722-52-9
eClass 6.1	32160405
eClass 9.0	32160490
Available
Description	InvivoChem Cat #:V30291CAS #:524722-52-9Purity >=98% Description: Vandetanib hydrochloride (formerly also known as ZD6474) is a novel, highly potent, orallybioavailable, selective inhibitor of VEGFR2 with IC50 of 40 nM in acell-free assay. Vandetanib selectively inhibits the tyrosine kinaseactivity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation andmigration and reducing tumor vessel permeability. The inhibition ofVEGFR-2 was 2.7-fold more potent than that of VEGFR-3 (Flt-4) kinase and40-fold more potent than that of VEGFR-1. In human umbilical veinendothelial cells, treatment of ZD6474 resulted in significantinhibition of cell proliferation stimulated by VEGF and EGF with IC50values of 60 and 170 nM, respectively. References: Cancer Res. 2002 Aug 15; 62(16):4645-55; Clin Cancer Res. 2012 Jul 15; 18(14):3924-33; Clin Cancer Res. 2003 Apr; 9(4):1546-56. Related CAS: 338992-00-0 (fumarate); 524722-52-9 (HCl salt); 338992-53-3 (trifluoroacetate); 443913-73-3 (free base) Description: Vandetanib hydrochloride (formerly also known as ZD6474) is a novel, highly potent, orallybioavailable, selective inhibitor of VEGFR2 with IC50 of 40 nM in acell-free assay. Vandetanib selectively inhibits the tyrosine kinaseactivity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation andmigration and reducing tumor vessel permeability. The inhibition ofVEGFR-2 was 2.7-fold more potent than that of VEGFR-3 (Flt-4) kinase and40-fold more potent than that of VEGFR-1. In human umbilical veinendothelial cells, treatment of ZD6474 resulted in significantinhibition of cell proliferation stimulated by VEGF and EGF with IC50values of 60 and 170 nM, respectively. References: Cancer Res. 2002 Aug 15; 62(16):4645-55; Clin Cancer Res. 2012 Jul 15; 18(14):3924-33; Clin Cancer Res. 2003 Apr; 9(4):1546-56. Related CAS: 338992-00-0 (fumarate); 524722-52-9 (HCl salt); 338992-53-3 (trifluoroacetate); 443913-73-3 (free base) Description: Vandetanib hydrochloride (formerly also known as ZD6474) is a novel, highly potent, orallybioavailable, selective inhibitor of VEGFR2 with IC50 of 40 nM in acell-free assay. Vandetanib selectively inhibits the tyrosine kinaseactivity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation andmigration and reducing tumor vessel permeability. The inhibition ofVEGFR-2 was 2.7-fold more potent than that of VEGFR-3 (Flt-4) kinase and40-fold more potent than that of VEGFR-1. In human umbilical veinendothelial cells, treatment of ZD6474 resulted in significantinhibition of cell proliferation stimulated by VEGF and EGF with IC50values of 60 and 170 nM, respectively. Description: References: Cancer Res. 2002 Aug 15; 62(16):4645-55; Clin Cancer Res. 2012 Jul 15; 18(14):3924-33; Clin Cancer Res. 2003 Apr; 9(4):1546-56. References:

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100mg

available

Delivery expected until 8/2/2024

Express Delivery: Save 7 days

Compare

Add to wishlist

Recommend by mail